ritonavir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
HIV protease inhibitors 2391 155213-67-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ABT538
  • ABT-538
  • ritonavir
  • norvir
Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease. Inhibition of HIV protease renders the enzyme incapable of processing the Gag-Pol polyprotein precursor which leads to production of non-infectious immature HIV particles.
  • Molecular weight: 720.95
  • Formula: C37H48N6O5S2
  • CLOGP: 4.94
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 4
  • TPSA: 145.78
  • ALOGS: -5.76
  • ROTB: 18

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O
0.80 g O
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 23.78 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 70 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
March 1, 1996 FDA ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 3544.17 52.11 906 4106 24313 2328760
Abortion spontaneous 2492.44 52.11 607 4405 12838 2340235
Foetal exposure during pregnancy 2237.44 52.11 469 4543 4783 2348290
Maternal exposure during pregnancy 1534.96 52.11 423 4589 14440 2338633
Abortion induced 927.64 52.11 212 4800 3224 2349849
Premature baby 926.03 52.11 209 4803 2995 2350078
Stillbirth 858.99 52.11 171 4841 1270 2351803
Live birth 847.08 52.11 166 4846 1125 2351948
Foetal death 657.70 52.11 144 4868 1768 2351305
Drug interaction 540.81 52.11 230 4782 28933 2324140
Premature delivery 538.63 52.11 135 4877 3065 2350008
Pregnancy 496.11 52.11 154 4858 7795 2345278
Caesarean section 491.83 52.11 132 4880 3949 2349124
Premature labour 477.61 52.11 113 4899 1993 2351080
Cushing's syndrome 406.22 52.11 83 4929 706 2352367
Premature rupture of membranes 383.28 52.11 81 4931 825 2352248
Foetal growth restriction 375.78 52.11 83 4929 1057 2352016
Immune reconstitution inflammatory syndrome 325.41 52.11 75 4937 1169 2351904
Lipodystrophy acquired 306.16 52.11 56 4956 243 2352830
Anaemia 304.15 52.11 164 4848 34628 2318445
Hyperbilirubinaemia 268.53 52.11 67 4945 1482 2351591
Pre-eclampsia 225.79 52.11 58 4954 1446 2351627
Hepatitis 219.74 52.11 79 4933 6258 2346815
Virologic failure 200.80 52.11 39 4973 247 2352826
Ventricular septal defect 186.10 52.11 44 4968 768 2352305
Vomiting 185.91 52.11 159 4853 71443 2281630
Hepatocellular injury 184.74 52.11 62 4950 3993 2349080
Pyrexia 181.06 52.11 139 4873 53569 2299504
Acute kidney injury 179.12 52.11 108 4904 28014 2325059
Gestational diabetes 176.89 52.11 47 4965 1340 2351733
Oligohydramnios 173.73 52.11 43 4969 917 2352156
Maternal drugs affecting foetus 171.81 52.11 47 4965 1500 2351573
Viral load increased 166.65 52.11 33 4979 234 2352839
Normal newborn 165.54 52.11 44 4968 1256 2351817
Trisomy 21 161.60 52.11 29 4983 110 2352963
Drug resistance 159.75 52.11 50 4962 2574 2350499
Treatment noncompliance 158.61 52.11 60 4952 5474 2347599
Congenital anomaly 157.99 52.11 35 4977 450 2352623
Renal colic 157.11 52.11 32 4980 266 2352807
HIV infection 154.84 52.11 28 4984 112 2352961
Polydactyly 153.87 52.11 27 4985 87 2352986
Cholestasis 142.60 52.11 50 4962 3671 2349402
Hepatotoxicity 141.97 52.11 49 4963 3432 2349641
Patent ductus arteriosus 141.35 52.11 34 4978 640 2352433
Congenital naevus 136.36 52.11 21 4991 19 2353054
Polyhydramnios 136.14 52.11 29 4983 306 2352767
Spina bifida 135.59 52.11 25 4987 114 2352959
Cholestasis of pregnancy 131.73 52.11 24 4988 101 2352972
Renal failure 129.73 52.11 74 4938 17275 2335798
Eosinophilia 129.67 52.11 44 4968 2926 2350147
Placenta praevia 127.54 52.11 26 4986 217 2352856
Rash 125.98 52.11 118 4894 59440 2293633
Diarrhoea 121.17 52.11 135 4877 83429 2269644
Viral mutation identified 120.46 52.11 25 4987 230 2352843
Cerebral ventricle dilatation 120.35 52.11 24 4988 177 2352896
Nausea 118.16 52.11 154 4858 112035 2241038
Low birth weight baby 114.81 52.11 30 4982 799 2352274
Skull malformation 114.57 52.11 21 4991 92 2352981
Placental insufficiency 114.38 52.11 24 4988 234 2352839
Rash maculo-papular 114.25 52.11 44 4968 4208 2348865
Jaundice 109.90 52.11 46 4966 5462 2347611
Low set ears 109.79 52.11 19 4993 55 2353018
Nephrolithiasis 104.46 52.11 42 4970 4501 2348572
Umbilical cord abnormality 103.87 52.11 20 4992 120 2352953
Placental disorder 102.79 52.11 23 4989 310 2352763
Cardiac murmur 102.72 52.11 32 4980 1619 2351454
CD4 lymphocytes decreased 99.76 52.11 23 4989 357 2352716
Alanine aminotransferase increased 97.25 52.11 57 4955 13975 2339098
Aspartate aminotransferase increased 94.76 52.11 54 4958 12558 2340515
Lactic acidosis 94.69 52.11 41 4971 5289 2347784
Adrenal suppression 94.47 52.11 19 4993 147 2352926
Sudden infant death syndrome 93.60 52.11 17 4995 70 2353003
Acoustic stimulation tests abnormal 91.98 52.11 15 4997 26 2353047
Osteoporosis 91.88 52.11 38 4974 4376 2348697
Atrial septal defect 87.61 52.11 27 4985 1317 2351756
Renal tubular disorder 87.47 52.11 22 4990 501 2352572
Congenital heart valve disorder 83.89 52.11 14 4998 30 2353043
Cloacal exstrophy 82.19 52.11 12 5000 4 2353069
Lipohypertrophy 81.46 52.11 16 4996 108 2352965
Anal atresia 81.41 52.11 15 4997 68 2353005
Supernumerary nipple 80.78 52.11 12 5000 6 2353067
Abdominal pain 80.06 52.11 72 4940 34302 2318771
Ectopic pregnancy 79.08 52.11 22 4990 746 2352327
Thrombocytopenia 78.74 52.11 56 4956 19075 2333998
Pancytopenia 77.96 52.11 46 4966 11406 2341667
Drug reaction with eosinophilia and systemic symptoms 77.44 52.11 36 4976 5482 2347591
Dysmorphism 77.41 52.11 19 4993 390 2352683
Bladder agenesis 76.66 52.11 11 5001 2 2353071
Weight increased 75.34 52.11 58 4954 22279 2330794
Asthenia 75.06 52.11 80 4932 46846 2306227
Hypercholesterolaemia 74.66 52.11 25 4987 1593 2351480
Cushingoid 74.57 52.11 20 4992 590 2352483
Gastrointestinal disorder congenital 74.38 52.11 11 5001 5 2353068
Transaminases increased 74.07 52.11 33 4979 4554 2348519
Congenital genital malformation 73.09 52.11 11 5001 7 2353066
Amniotic cavity infection 71.79 52.11 17 4995 298 2352775
Exomphalos 71.67 52.11 13 4999 53 2353020
General physical health deterioration 71.47 52.11 47 4965 14092 2338981
Hypertriglyceridaemia 71.32 52.11 21 4991 875 2352198
Hepatic enzyme increased 71.01 52.11 41 4971 9761 2343312
Mitochondrial cytopathy 70.19 52.11 13 4999 61 2353012
Vertigo 69.98 52.11 40 4972 9344 2343729
Trisomy 18 69.52 52.11 12 5000 34 2353039
Meningomyelocele 69.50 52.11 13 4999 65 2353008
Genitalia external ambiguous 69.04 52.11 11 5001 15 2353058
Meconium stain 68.53 52.11 12 5000 38 2353035
Small for dates baby 68.19 52.11 19 4993 648 2352425
Fanconi syndrome 67.17 52.11 15 4997 200 2352873
Congenital pulmonary valve disorder 67.11 52.11 11 5001 20 2353053
Portal hypertension 67.04 52.11 18 4994 533 2352540
Human immunodeficiency virus transmission 66.67 52.11 10 5002 6 2353067
Blood bilirubin increased 66.20 52.11 32 4980 5313 2347760
Adrenal insufficiency 66.06 52.11 22 4990 1378 2351695
Foetal distress syndrome 65.62 52.11 16 4996 319 2352754
Depression 65.62 52.11 59 4953 28073 2325000
Multiple-drug resistance 65.47 52.11 15 4997 226 2352847
Retinoblastoma 64.87 52.11 11 5001 27 2353046
Tethered cord syndrome 64.59 52.11 11 5001 28 2353045
Liver function test abnormal 64.22 52.11 35 4977 7455 2345618
Neural tube defect 63.77 52.11 11 5001 31 2353042
Cerebral toxoplasmosis 63.08 52.11 13 4999 115 2352958
Single umbilical artery 62.77 52.11 11 5001 35 2353038
Metabolic acidosis 62.70 52.11 32 4980 5966 2347107
Hyperlactacidaemia 62.45 52.11 16 4996 393 2352680
Anembryonic gestation 62.40 52.11 14 4998 191 2352882
Neutropenia 62.05 52.11 51 4961 21497 2331576
Coarctation of the aorta 60.35 52.11 13 4999 145 2352928
Caudal regression syndrome 60.06 52.11 10 5002 21 2353052
Spine malformation 59.86 52.11 11 5001 49 2353024
Foetal malnutrition 59.74 52.11 10 5002 22 2353051
Pathogen resistance 59.47 52.11 18 4994 825 2352248
Gastrointestinal malformation 58.84 52.11 10 5002 25 2353048
Neonatal respiratory arrest 58.84 52.11 10 5002 25 2353048
Oesophageal candidiasis 58.76 52.11 17 4995 665 2352408
Hepatic failure 58.45 52.11 30 4982 5659 2347414
Hydrocephalus 58.25 52.11 18 4994 885 2352188
Microcephaly 55.37 52.11 12 5000 138 2352935
Ventricular hypertrophy 54.96 52.11 16 4996 640 2352433
Pulmonary tuberculosis 54.39 52.11 17 4995 868 2352205
Ergot poisoning 54.15 52.11 10 5002 46 2353027
Proteinuria 54.14 52.11 23 4989 2827 2350246
Weight decreased 53.69 52.11 53 4959 28318 2324755
Face oedema 53.04 52.11 25 4987 3923 2349150
Congenital central nervous system anomaly 52.91 52.11 11 5001 102 2352971
Hypokalaemia 52.81 52.11 35 4977 10619 2342454
Gestational hypertension 52.75 52.11 14 4998 396 2352677
Talipes 52.63 52.11 13 4999 274 2352799
Alpha 1 foetoprotein abnormal 52.54 52.11 9 5003 24 2353049

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Foetal exposure during pregnancy 1854.92 31.15 495 6798 5864 1733624
Immune reconstitution inflammatory syndrome 1157.59 31.15 258 7035 1291 1738197
Drug interaction 917.59 31.15 427 6866 27531 1711957
Lipodystrophy acquired 912.94 31.15 167 7126 206 1739282
Premature baby 645.66 31.15 184 7109 2758 1736730
Diarrhoea 565.10 31.15 390 6903 53462 1686026
Exposure during pregnancy 484.84 31.15 146 7147 2671 1736817
Mitochondrial toxicity 478.19 31.15 88 7205 114 1739374
Cushing's syndrome 474.48 31.15 105 7188 499 1738989
Acute kidney injury 469.64 31.15 296 6997 34648 1704840
Nephrolithiasis 426.83 31.15 144 7149 3848 1735640
Renal tubular disorder 399.93 31.15 98 7195 777 1738711
Pyrexia 391.25 31.15 295 6998 46105 1693383
Osteonecrosis 388.63 31.15 134 7159 3828 1735660
Hyperbilirubinaemia 386.80 31.15 117 7176 2170 1737318
Nausea 365.50 31.15 295 6998 50901 1688587
Osteoporosis 362.16 31.15 102 7191 1453 1738035
Progressive external ophthalmoplegia 354.00 31.15 57 7236 3 1739485
Eyelid ptosis 344.18 31.15 84 7209 653 1738835
Jaundice 336.57 31.15 135 7158 5927 1733561
Hypertriglyceridaemia 316.79 31.15 87 7206 1122 1738366
Vomiting 314.39 31.15 240 7053 38075 1701413
Renal failure 309.78 31.15 186 7107 19831 1719657
Anaemia 306.16 31.15 213 7080 29244 1710244
Hepatitis 305.27 31.15 119 7174 4836 1734652
Hyperlipidaemia 296.84 31.15 95 7198 2134 1737354
Renal colic 295.84 31.15 68 7225 394 1739094
Renal impairment 276.04 31.15 146 7147 12168 1727320
Alanine aminotransferase increased 242.83 31.15 134 7159 12144 1727344
Kaposi's sarcoma 234.55 31.15 64 7229 803 1738685
Blood bilirubin increased 230.50 31.15 104 7189 6106 1733382
Blood triglycerides increased 224.33 31.15 80 7213 2520 1736968
Virologic failure 224.20 31.15 53 7240 353 1739135
Weight decreased 220.84 31.15 158 7135 22595 1716893
Aspartate aminotransferase increased 219.83 31.15 120 7173 10636 1728852
Pancytopenia 219.19 31.15 122 7171 11235 1728253
Diplopia 217.67 31.15 78 7215 2492 1736996
Fanconi syndrome 211.94 31.15 49 7244 292 1739196
Hyperlactacidaemia 209.84 31.15 50 7243 346 1739142
Mycobacterium avium complex infection 201.75 31.15 47 7246 291 1739197
Abdominal pain 201.09 31.15 146 7147 21344 1718144
Thrombocytopenia 200.28 31.15 145 7148 21104 1718384
Polydactyly 186.65 31.15 41 7252 186 1739302
Drug reaction with eosinophilia and systemic symptoms 185.20 31.15 84 7209 4986 1734502
Trisomy 21 181.79 31.15 36 7257 85 1739403
Gamma-glutamyltransferase increased 181.60 31.15 83 7210 5015 1734473
Viral load increased 180.98 31.15 48 7245 536 1738952
Dyslipidaemia 173.44 31.15 50 7243 775 1738713
Depression 171.37 31.15 120 7173 16549 1722939
Fatigue 162.87 31.15 189 7104 50592 1688896
Liver disorder 161.55 31.15 79 7214 5557 1733931
HIV-associated neurocognitive disorder 160.74 31.15 30 7263 44 1739444
Headache 159.90 31.15 156 7137 34220 1705268
Progressive multifocal leukoencephalopathy 158.80 31.15 55 7238 1584 1737904
Proteinuria 156.45 31.15 63 7230 2781 1736707
Foetal growth restriction 155.20 31.15 44 7249 640 1738848
Cytomegalovirus chorioretinitis 154.31 31.15 39 7254 354 1739134
Lactic acidosis 153.33 31.15 74 7219 5055 1734433
Asthenia 153.19 31.15 153 7140 34517 1704971
Drug resistance 152.03 31.15 64 7229 3166 1736322
Ventricular septal defect 149.60 31.15 44 7249 734 1738754
Pancreatitis 148.97 31.15 81 7212 7106 1732382
Fanconi syndrome acquired 147.39 31.15 39 7254 431 1739057
Hepatic cirrhosis 146.72 31.15 59 7234 2594 1736894
Pneumonia 146.50 31.15 171 7122 46011 1693477
Pneumocystis jirovecii pneumonia 144.10 31.15 57 7236 2399 1737089
Rash 142.68 31.15 155 7138 38538 1700950
Maternal drugs affecting foetus 139.90 31.15 46 7247 1125 1738363
Congenital anomaly 136.53 31.15 36 7257 392 1739096
CD4 lymphocytes decreased 135.54 31.15 36 7257 404 1739084
Neuropathy peripheral 135.02 31.15 83 7210 9170 1730318
Cardiac murmur 134.00 31.15 45 7248 1177 1738311
Cholelithiasis 133.39 31.15 58 7235 3107 1736381
Myocardial infarction 133.17 31.15 127 7166 27047 1712441
Hepatotoxicity 131.56 31.15 57 7236 3027 1736461
Cholestasis 128.36 31.15 59 7234 3606 1735882
Blood creatinine increased 126.27 31.15 93 7200 13853 1725635
Rash maculo-papular 124.67 31.15 58 7235 3645 1735843
Diabetes mellitus 124.41 31.15 71 7222 6837 1732651
Lipoatrophy 124.38 31.15 26 7267 88 1739400
Insomnia 124.18 31.15 98 7195 16178 1723310
Low birth weight baby 122.91 31.15 39 7254 848 1738640
Myalgia 121.00 31.15 95 7198 15563 1723925
General physical health deterioration 119.92 31.15 88 7205 13030 1726458
Ascites 118.62 31.15 64 7229 5522 1733966
Abdominal distension 118.11 31.15 67 7226 6377 1733111
HIV infection 117.65 31.15 29 7264 235 1739253
Nephropathy toxic 115.06 31.15 44 7249 1688 1737800
Hypercholesterolaemia 114.80 31.15 40 7253 1172 1738316
Hepatitis C 113.79 31.15 50 7243 2746 1736742
Cryptorchism 113.24 31.15 30 7263 333 1739155
Blood cholesterol increased 113.17 31.15 51 7242 2975 1736513
Hepatomegaly 112.63 31.15 43 7250 1642 1737846
Hepatic function abnormal 112.30 31.15 67 7226 7007 1732481
Cushingoid 111.10 31.15 30 7263 360 1739128
Pruritus 110.80 31.15 107 7186 23115 1716373
Hypokalaemia 110.73 31.15 64 7229 6310 1733178
Blood creatine phosphokinase increased 110.58 31.15 72 7221 8784 1730704
Lymphadenopathy 109.92 31.15 55 7238 4059 1735429
Acquired immunodeficiency syndrome 108.67 31.15 23 7270 84 1739404
Neutropenia 108.21 31.15 95 7198 18165 1721323
Hypophosphataemia 108.06 31.15 39 7254 1269 1738219
Oral candidiasis 108.03 31.15 39 7254 1270 1738218
Atypical mycobacterial infection 107.95 31.15 25 7268 150 1739338
Pancreatitis acute 107.31 31.15 54 7239 4033 1735455
Malaise 106.31 31.15 117 7176 29448 1710040
Dysphagia 106.21 31.15 74 7219 10094 1729394
Blood alkaline phosphatase increased 106.07 31.15 58 7235 5137 1734351
Adrenal insufficiency 102.74 31.15 38 7255 1327 1738161
Blood lactic acid increased 102.11 31.15 34 7259 865 1738623
Hypertension 101.11 31.15 94 7199 19354 1720134
Hyperuricaemia 99.20 31.15 34 7259 947 1738541
Dehydration 98.91 31.15 89 7204 17569 1721919
Cerebral toxoplasmosis 97.27 31.15 23 7270 153 1739335
Oesophageal atresia 96.53 31.15 20 7273 64 1739424
Transaminases increased 94.83 31.15 49 7244 3868 1735620
Portal hypertension 94.37 31.15 30 7263 656 1738832
Hepatic failure 93.91 31.15 56 7237 5847 1733641
Hepatic steatosis 91.72 31.15 42 7251 2542 1736946
Lipohypertrophy 91.65 31.15 19 7274 61 1739427
Tubulointerstitial nephritis 89.32 31.15 43 7250 2915 1736573
Ocular icterus 89.23 31.15 28 7265 586 1738902
Dyspnoea 87.58 31.15 142 7151 51917 1687571
Oesophageal candidiasis 87.14 31.15 27 7266 541 1738947
Calculus urinary 85.79 31.15 23 7270 268 1739220
Syphilis 85.62 31.15 19 7274 91 1739397
Depressed mood 85.53 31.15 42 7251 2974 1736514
Adrenal suppression 84.59 31.15 20 7273 133 1739355
Congenital hydronephrosis 83.36 31.15 19 7274 105 1739383
Gastrointestinal disorder 83.31 31.15 48 7245 4700 1734788
Hepatocellular injury 82.79 31.15 42 7251 3189 1736299
Drug level increased 82.74 31.15 40 7253 2737 1736751
Cortisol decreased 82.45 31.15 21 7272 197 1739291
Leukopenia 82.24 31.15 59 7234 8421 1731067
Weight increased 81.45 31.15 66 7227 11291 1728197
Cough 81.39 31.15 83 7210 19114 1720374
Atrial septal defect 81.32 31.15 32 7261 1326 1738162
Lymphoma 80.74 31.15 36 7257 2046 1737442
Metabolic acidosis 80.12 31.15 49 7244 5353 1734135
Liver function test abnormal 80.01 31.15 50 7243 5676 1733812
Blood bilirubin unconjugated increased 79.87 31.15 20 7273 174 1739314
Coronary artery disease 78.71 31.15 61 7232 9785 1729703
Nervous system disorder 78.13 31.15 37 7256 2417 1737071
Small for dates baby 77.40 31.15 25 7268 576 1738912
Spinal compression fracture 75.66 31.15 27 7266 849 1738639
Gastritis 75.46 31.15 39 7254 3078 1736410
Viral mutation identified 75.39 31.15 22 7271 356 1739132
Rhabdomyolysis 74.39 31.15 62 7231 11028 1728460
Arthralgia 74.36 31.15 87 7206 23357 1716131
Herpes zoster 74.33 31.15 44 7249 4529 1734959
Vertigo 73.14 31.15 43 7250 4370 1735118
Acute myocardial infarction 72.58 31.15 55 7238 8532 1730956
Hyponatraemia 72.46 31.15 56 7237 8944 1730544
Hyperglycaemia 71.90 31.15 45 7248 5120 1734368
Condition aggravated 69.59 31.15 80 7213 21070 1718418
Myositis 69.55 31.15 30 7263 1573 1737915
Blood HIV RNULL increased 68.33 31.15 18 7275 195 1739293
Hepatosplenomegaly 68.01 31.15 23 7270 614 1738874
Glycosuria 67.66 31.15 19 7274 266 1739222
Mitochondrial cytopathy 66.82 31.15 14 7279 48 1739440
Treatment noncompliance 66.63 31.15 43 7250 5158 1734330
Decreased appetite 66.57 31.15 83 7210 23788 1715700
Abdominal hernia 66.50 31.15 20 7273 361 1739127
Ophthalmoplegia 66.35 31.15 18 7275 220 1739268
Ergot poisoning 65.38 31.15 12 7281 15 1739473
Renal tubular necrosis 64.56 31.15 31 7262 2088 1737400
Varices oesophageal 64.33 31.15 22 7271 608 1738880
Hepatic enzyme increased 64.03 31.15 46 7247 6575 1732913
Chronic kidney disease 63.60 31.15 39 7254 4278 1735210
Hodgkin's disease 63.31 31.15 23 7270 762 1738726
Cytomegalovirus infection 62.27 31.15 35 7258 3266 1736222
Oedema peripheral 61.85 31.15 65 7228 15485 1724003
Encephalitis 61.82 31.15 25 7268 1113 1738375
Candida infection 60.73 31.15 29 7264 1929 1737559
Anogenital warts 60.36 31.15 15 7278 126 1739362
Sepsis 59.72 31.15 71 7222 19367 1720121
Suicide attempt 59.56 31.15 46 7247 7335 1732153
Splenomegaly 58.54 31.15 29 7264 2091 1737397
Heterotaxia 58.19 31.15 11 7282 18 1739470
Overdose 58.01 31.15 65 7228 16636 1722852
Cachexia 57.54 31.15 23 7270 993 1738495
Haemophilic arthropathy 56.45 31.15 11 7282 23 1739465
Toxic skin eruption 55.71 31.15 27 7266 1856 1737632
Low set ears 55.43 31.15 13 7280 83 1739405
Dizziness 55.30 31.15 92 7201 34269 1705219
Cerebral ventricle dilatation 55.23 31.15 15 7278 184 1739304
Hemivertebra 55.23 31.15 11 7282 27 1739461
Disturbance in attention 54.21 31.15 35 7258 4199 1735289
Genital herpes 53.67 31.15 13 7280 97 1739391
Septic shock 53.66 31.15 45 7248 8064 1731424
Platelet count decreased 53.48 31.15 62 7231 16461 1723027
Treatment failure 52.98 31.15 35 7258 4366 1735122
Abdominal pain upper 52.93 31.15 51 7242 10950 1728538
Renal disorder 52.87 31.15 34 7259 4052 1735436
Genital herpes simplex 52.67 31.15 10 7283 17 1739471
Osteoporotic fracture 52.46 31.15 14 7279 160 1739328
Hepatitis cholestatic 51.72 31.15 23 7270 1298 1738190
Seizure 50.56 31.15 67 7226 20374 1719114
Hepatitis B 50.39 31.15 23 7270 1380 1738108
Gastroenteritis 50.22 31.15 26 7267 2058 1737430
Tachypnoea 49.97 31.15 27 7266 2331 1737157
Cell death 49.76 31.15 16 7277 363 1739125
Eosinophilia 49.76 31.15 31 7262 3496 1735992
Caesarean section 49.52 31.15 18 7275 597 1738891
Agranulocytosis 49.36 31.15 31 7262 3545 1735943
Vanishing bile duct syndrome 48.92 31.15 13 7280 146 1739342
Mycobacterial infection 48.90 31.15 15 7278 290 1739198
Femoral neck fracture 48.87 31.15 17 7276 495 1738993
Anal cancer 48.70 31.15 12 7281 97 1739391
Enanthema 48.70 31.15 12 7281 97 1739391
Polyneuropathy 48.43 31.15 24 7269 1731 1737757
Pyelocaliectasis 48.36 31.15 13 7280 153 1739335
HIV associated nephropathy 48.29 31.15 9 7284 13 1739475
Foetal distress syndrome 47.94 31.15 14 7279 227 1739261
Patent ductus arteriosus 47.79 31.15 18 7275 661 1738827
Fibrous histiocytoma 47.35 31.15 10 7283 36 1739452
Drug-induced liver injury 47.05 31.15 29 7264 3208 1736280
Toxicity to various agents 46.83 31.15 78 7215 29063 1710425
Uveitis 46.68 31.15 20 7273 1031 1738457
Ear malformation 46.03 31.15 11 7282 77 1739411
Ureterolithiasis 45.78 31.15 15 7278 362 1739126
Coma 45.38 31.15 39 7254 7223 1732265
Retinal toxicity 45.05 31.15 12 7281 136 1739352
Dysmorphism 45.01 31.15 15 7278 382 1739106
Normal newborn 44.81 31.15 12 7281 139 1739349
Congenital mitral valve incompetence 44.38 31.15 9 7284 25 1739463
Haemolytic anaemia 44.20 31.15 23 7270 1839 1737649
Staphylococcal infection 43.89 31.15 32 7261 4675 1734813
C-reactive protein increased 43.85 31.15 35 7258 5850 1733638
Herpes simplex 43.61 31.15 17 7276 686 1738802
Amylase increased 43.32 31.15 20 7273 1232 1738256
Bone marrow failure 43.24 31.15 33 7260 5167 1734321
Meningitis cryptococcal 42.91 31.15 14 7279 333 1739155
Pathogen resistance 42.75 31.15 19 7274 1070 1738418
Stillbirth 42.75 31.15 10 7283 63 1739425
Intestinal malrotation 42.75 31.15 8 7285 12 1739476
Oral herpes 42.65 31.15 17 7276 728 1738760
Porphyria non-acute 42.46 31.15 11 7282 111 1739377
Embolism 42.29 31.15 19 7274 1098 1738390
Hyperadrenocorticism 42.27 31.15 9 7284 34 1739454
Prenatal screening test abnormal 42.05 31.15 7 7286 2 1739486
Face oedema 41.98 31.15 24 7269 2312 1737176
Hydronephrosis 41.95 31.15 20 7273 1325 1738163
Spine malformation 41.48 31.15 9 7284 38 1739450
Chills 41.44 31.15 46 7247 11641 1727847
Radius fracture 40.88 31.15 11 7282 130 1739358
Drug intolerance 40.84 31.15 34 7259 6028 1733460
Congenital choroid plexus cyst 40.74 31.15 9 7284 42 1739446
Foetal chromosome abnormality 40.65 31.15 7 7286 4 1739484
Haemoglobin decreased 40.62 31.15 55 7238 17059 1722429
Amyotrophy 40.57 31.15 11 7282 134 1739354
Renal aplasia 40.42 31.15 11 7282 136 1739352
Neonatal hyponatraemia 39.78 31.15 8 7285 21 1739467
Kidney malformation 39.59 31.15 9 7284 49 1739439
Epilepsy 39.39 31.15 28 7265 3931 1735557
Live birth 39.29 31.15 9 7284 51 1739437
Pyelonephritis 39.16 31.15 16 7277 731 1738757
Leishmaniasis 38.71 31.15 9 7284 55 1739433
Encephalopathy 38.66 31.15 29 7264 4423 1735065
Gastroschisis 38.51 31.15 8 7285 26 1739462
Erectile dysfunction 38.40 31.15 29 7264 4468 1735020
Prurigo 38.34 31.15 11 7282 167 1739321
Volvulus 38.19 31.15 12 7281 252 1739236
Secondary adrenocortical insufficiency 37.98 31.15 11 7282 173 1739315
Congenital aortic anomaly 37.84 31.15 8 7285 29 1739459
Cerebral haemorrhage 37.78 31.15 33 7260 6244 1733244
Congenital renal disorder 37.42 31.15 8 7285 31 1739457
Multiple organ dysfunction syndrome 37.37 31.15 39 7254 9203 1730285
Psychiatric decompensation 37.37 31.15 12 7281 271 1739217
Hypoaesthesia 37.10 31.15 40 7253 9795 1729693
Wrong dose 36.71 31.15 9 7284 71 1739417
Blood lactate dehydrogenase increased 36.58 31.15 26 7267 3649 1735839
Visceral leishmaniasis 36.50 31.15 10 7283 127 1739361
Stevens-Johnson syndrome 36.33 31.15 25 7268 3332 1736156
Skin exfoliation 36.00 31.15 28 7265 4507 1734981
Back pain 35.85 31.15 51 7242 16562 1722926
Oropharyngeal candidiasis 35.74 31.15 10 7283 138 1739350
Basedow's disease 35.65 31.15 11 7282 217 1739271
Limb malformation 35.27 31.15 9 7284 85 1739403
Ileus paralytic 35.19 31.15 16 7277 951 1738537
Hypersensitivity 35.13 31.15 40 7253 10404 1729084
Kidney enlargement 35.03 31.15 10 7283 149 1739339
CD4 lymphocytes abnormal 34.91 31.15 7 7286 18 1739470
Hyperthermia 34.82 31.15 19 7274 1672 1737816
Staphylococcal sepsis 34.51 31.15 17 7276 1210 1738278
Exomphalos 34.39 31.15 8 7285 49 1739439
Haematuria 34.39 31.15 34 7259 7526 1731962
Vitamin D deficiency 34.21 31.15 13 7280 489 1738999
Hyperphagia 34.15 31.15 11 7282 251 1739237
Loss of consciousness 34.08 31.15 47 7246 14828 1724660
Pulmonary tuberculosis 33.70 31.15 16 7277 1050 1738438
Shock 33.70 31.15 26 7267 4135 1735353
Congenital hearing disorder 33.64 31.15 7 7286 23 1739465
Superior mesenteric artery syndrome 33.64 31.15 7 7286 23 1739465
Blood phosphorus decreased 33.53 31.15 13 7280 517 1738971
Dermatitis exfoliative 33.42 31.15 18 7275 1543 1737945
Death 32.83 31.15 135 7158 87308 1652180
Appendicitis 32.57 31.15 16 7277 1132 1738356
Anogenital dysplasia 32.56 31.15 7 7286 28 1739460
Blood antidiuretic hormone increased 32.56 31.15 7 7286 28 1739460
Congenital bladder anomaly 32.37 31.15 7 7286 29 1739459
Glucose urine present 32.33 31.15 10 7283 199 1739289
Dyschromatopsia 32.21 31.15 8 7285 67 1739421
Iron deficiency anaemia 32.18 31.15 16 7277 1162 1738326
Folate deficiency 32.18 31.15 9 7284 124 1739364
Lymphadenitis 32.12 31.15 11 7282 305 1739183
Maculopathy 32.09 31.15 11 7282 306 1739182
Optic neuritis 31.78 31.15 14 7279 772 1738716
Seborrhoeic dermatitis 31.69 31.15 10 7283 213 1739275
Pneumococcal sepsis 31.66 31.15 9 7284 132 1739356
Renal tubular acidosis 31.56 31.15 11 7282 322 1739166
Chest pain 31.55 31.15 53 7240 19861 1719627
Facial wasting 31.46 31.15 7 7286 34 1739454
Blood uric acid increased 31.45 31.15 15 7278 994 1738494

Pharmacologic Action:

SourceCodeDescription
ATC J05AE03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Protease inhibitors
ATC J05AP52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AP53 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
ATC J05AR10 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR23 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR26 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA EPC N0000191001 Cytochrome P450 3A Inhibitor
FDA EPC N0000175889 Protease Inhibitor
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185607 Cytochrome P450 2C19 Inducers
FDA MoA N0000190118 Cytochrome P450 3A Inducers
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190113 Breast Cancer Resistance Protein Inhibitors
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
FDA MoA N0000191266 Cytochrome P450 1A2 Inducers
FDA MoA N0000185507 Cytochrome P450 2C9 Inducers
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000190117 UDP Glucuronosyltransferases Inducers
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D065692 Cytochrome P-450 CYP3A Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D017320 HIV Protease Inhibitors
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:36044 antiviral drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Chronic hepatitis C indication 128302006
Coronavirus infection off-label use 186747009
Prevention of HIV Infection after Exposure off-label use
Hypercholesterolemia contraindication 13644009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Cirrhosis of liver contraindication 19943007 DOID:5082
Complete atrioventricular block contraindication 27885002
Hereditary factor VIII deficiency disease contraindication 28293008 DOID:12134
Torsades de pointes contraindication 31722008
Hyperuricemia contraindication 35885006 DOID:1920
Hereditary factor IX deficiency disease contraindication 41788008 DOID:12259
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Chronic type B viral hepatitis contraindication 61977001
Diabetes mellitus contraindication 73211009 DOID:9351
Pancreatitis contraindication 75694006 DOID:4989
Hyperglycemia contraindication 80394007 DOID:4195
Cardiomyopathy contraindication 85898001 DOID:0050700
Gout contraindication 90560007 DOID:13189
Prolonged QT interval contraindication 111975006
Structural disorder of heart contraindication 128599005
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Second degree atrioventricular block contraindication 195042002
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Mixed hyperlipidemia contraindication 267434003
Hypertriglyceridemia contraindication 302870006
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Congenital long QT syndrome contraindication 442917000
First Degree Atrioventricular Heart Block contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.39 acidic
pKa2 13.84 acidic
pKa3 3.62 Basic
pKa4 2.45 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8501238 Sept. 17, 2028 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9139536 Nov. 9, 2028 TREATMENT OF HCV INFECTION USING DASABUVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8188104 May 17, 2029 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
50MG TECHNIVIE ABBVIE INC N207931 July 24, 2015 DISCN TABLET ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8642538 Sept. 10, 2029 TREATMENT OF HCV INFECTION USING PARITAPREVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
50MG TECHNIVIE ABBVIE INC N207931 July 24, 2015 DISCN TABLET ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9006387 June 10, 2030 TREATMENT OF HCV INFECTION USING OMBITASVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
50MG TECHNIVIE ABBVIE INC N207931 July 24, 2015 DISCN TABLET ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9044480 April 10, 2031 TREATMENT OF HCV INFECTION USING PARITAPREVIR
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10201584 May 17, 2032 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8466159 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8492386 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8680106 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 8685984 Sept. 4, 2032 TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 10201542 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
None VIEKIRA PAK (COPACKAGED) ABBVIE INC N206619 Dec. 19, 2014 RX TABLET, TABLET ORAL 9629841 Oct. 18, 2033 TREATMENT OF HCV INFECTION USING DASABUVIR
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 10105365 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9333204 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
33.33MG VIEKIRA XR ABBVIE INC N208624 July 22, 2016 DISCN TABLET, EXTENDED RELEASE ORAL 9744170 Jan. 2, 2035 TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 2D6 Enzyme IC50 4.30 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 5.26 DRUG MATRIX
Cytochrome P450 2C9 Enzyme IC50 7.80 DRUG MATRIX
Vasopressin V1a receptor GPCR Ki 5.30 DRUG MATRIX
Thromboxane-A synthase Enzyme IC50 7.12 DRUG MATRIX
Substance-K receptor GPCR Ki 6.06 DRUG MATRIX
Cytochrome P450 3A4 Enzyme IC50 7.55 WOMBAT-PK
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor WOMBAT-PK
Multidrug resistance protein 1 Transporter IC50 5.83 WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.47 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.61 CHEMBL
Multidrug and toxin extrusion protein 2 Transporter IC50 5.36 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 7.10 CHEMBL
Mu-type opioid receptor GPCR Ki 4.58 DRUG MATRIX
Pol polyprotein Enzyme INHIBITOR Ki 10.82 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein Ki 9.23 WOMBAT-PK
Protease Enzyme Ki 10.47 CHEMBL

External reference:

IDSource
4020963 VUID
N0000148436 NUI
C0292818 UMLSCUI
D00427 KEGG_DRUG
108693005 SNOMEDCT_US
4020963 VANDF
005554 NDDF
85762 RXNORM
386896009 SNOMEDCT_US
5431 MMSL
d03984 MMSL
251788 MMSL
CHEMBL163 ChEMBL_ID
DB00503 DRUGBANK_ID
O3J8G9O825 UNII
7449 INN_ID
RIT PDB_CHEM_ID
CHEBI:45409 CHEBI
D019438 MESH_DESCRIPTOR_UI
392622 PUBCHEM_CID
8804 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 0054-0407 TABLET, FILM COATED 100 mg ORAL ANDA 20 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 0074-0522 TABLET, FILM COATED 25 mg ORAL NDA 18 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 0074-1575 TABLET, FILM COATED 25 mg ORAL NDA 18 sections
Norvir HUMAN PRESCRIPTION DRUG LABEL 1 0074-1940 SOLUTION 80 mg ORAL NDA 21 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 0074-2605 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Viekira Pak HUMAN PRESCRIPTION DRUG LABEL 4 0074-3093 KIT 50 mg None NDA 19 sections
Norvir HUMAN PRESCRIPTION DRUG LABEL 1 0074-3333 TABLET, FILM COATED 100 mg ORAL NDA 21 sections
Norvir HUMAN PRESCRIPTION DRUG LABEL 1 0074-3399 POWDER 100 mg ORAL NDA 21 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 0074-3956 SOLUTION 20 mg ORAL NDA 18 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 0074-6799 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Lopinavir-Ritonavir HUMAN PRESCRIPTION DRUG LABEL 2 0527-1947 SOLUTION 20 mg ORAL ANDA 19 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 11819-342 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 21695-362 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 31722-597 TABLET 100 mg ORAL ANDA 20 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 53808-0276 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Norvir HUMAN PRESCRIPTION DRUG LABEL 1 53808-1119 TABLET, FILM COATED 100 mg ORAL NDA 20 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 54868-5566 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 55289-947 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 60687-364 TABLET, FILM COATED 100 mg ORAL ANDA 21 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 60687-420 TABLET, FILM COATED 100 mg ORAL ANDA 21 sections
Lopinavir and Ritonavir HUMAN PRESCRIPTION DRUG LABEL 2 65015-299 GRANULE 10 mg ORAL Export only 1 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 65162-061 TABLET 100 mg ORAL ANDA 20 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 65862-687 TABLET, FILM COATED 100 mg ORAL ANDA 20 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 66336-624 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Norvir HUMAN PRESCRIPTION DRUG LABEL 1 67296-1234 TABLET, FILM COATED 100 mg ORAL NDA 19 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 68258-1972 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Kaletra HUMAN PRESCRIPTION DRUG LABEL 2 70518-0091 TABLET, FILM COATED 50 mg ORAL NDA 18 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 70518-1086 TABLET, FILM COATED 100 mg ORAL ANDA 19 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 70518-1519 TABLET 100 mg ORAL ANDA 20 sections
Ritonavir HUMAN PRESCRIPTION DRUG LABEL 1 70518-2007 TABLET, FILM COATED 100 mg ORAL ANDA 20 sections